Hu Xiaoyong, Chen Xiaochun, Ping Hao, Chen Zhaohui, Zeng Fuqing, Lu Gongcheng
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
J Huazhong Univ Sci Technolog Med Sci. 2005;25(6):671-3. doi: 10.1007/BF02896167.
To study the expression and significance of the serine protease Omi/HtrA2 in prostate cancer and benign prostatic hyperplasia. The expression of Omi/HtrA2 was assayed by means of immunohistochemical technique in 41 prostate cancer (Cap), 20 benign prostatic hyperplasia (BPH) and 10 normal prostate (NP) specimens. Omi/HtrA2 expression was positive in 30 (73.17%) prostate cancer specimens, and the positive rate of Omi/HtrA2 was lower in well differentiated than in poorly and moderately differentiated groups (P < 0.05). By contrast, the cells in normal prostate and benign prostatic hyperplasia groups showed no or weak expression of Omi/HtrA2. Prostate cancer cells in vivo may need Omi/HtrA2 expression for apoptosis, and that Omi/HtrA2 expression might be involved in prostate cancer development.
研究丝氨酸蛋白酶Omi/HtrA2在前列腺癌和良性前列腺增生中的表达及意义。采用免疫组化技术检测41例前列腺癌（Cap）、20例良性前列腺增生（BPH）和10例正常前列腺（NP）标本中Omi/HtrA2的表达。30例（73.17%）前列腺癌标本中Omi/HtrA2表达呈阳性，高分化组Omi/HtrA2阳性率低于低分化和中分化组（P < 0.05）。相比之下，正常前列腺和良性前列腺增生组细胞中Omi/HtrA2无表达或呈弱表达。前列腺癌细胞在体内可能需要Omi/HtrA2表达来进行凋亡，且Omi/HtrA2表达可能参与前列腺癌的发生发展。
